Bitcoin’s Big Apple Buzz

TLDR

• JPMorgan foresees Bitcoin hitting a wild $165K by 2025. They’re linking this to ETF demand and gold ties.
• Over at Citi, the projection’s more chill, with a $133K estimate if ETF flows continue strong.
• Standard Chartered’s really shooting for the stars, expecting $200K by December.
• Bitcoin’s price pop is tied to ETF growth and a shift from gold to digital currency.

So, what’s got Wall Street abuzz with Bitcoin fever? Let’s dive into the latest forecasts and why big banks are seeing dollar signs.

JPMorgan’s Vision

JPMorgan’s got their calculators out and they’re talking serious numbers—$165,000 by 2025. They say Bitcoin’s reading gold its last rites, with volatility taking center stage. Compared to gold, Bitcoin’s become the asset everyone’s eyeing.

Their analysts note the Bitcoin-to-gold volatility ratio dropping below two, hinting at juicy gains if people keep bailing on gold and hopping onto the Bitcoin train. ETF demand hasn’t exactly hurt things either.

Citi’s Cautious Call

Citi’s being a bit more reserved, penciling Bitcoin in at $133,000 this year. Sounds good, right? But they’re playing the cautious card, pointing out that uncertainties in the macroeconomic world could damper things.

They tip their hat to U.S.-based Bitcoin ETFs managing a hefty $163 billion in digital gold. Another $7.5 billion in ETF bits and bobs might just keep Bitcoin cruising upward. Yet, if things tank, a price of $83,000 isn’t off the table. You know, doom and gloom just in case.

Standard Chartered’s Sky-High Hope

Standard Chartered’s betting big with a $200,000 forecast by December. They’re banking on ETFs and institutions warming up to our digital buddy. A weaker U.S. dollar and better global liquidity don’t hurt the cause, either.

Now, let’s not forget VanEck, holding onto a $180,000 vision by 2025. They’re eyeing the Bitcoin halving events like they’ve got a crystal ball. That supply squeeze could set the stage for some heady days, with ETFs fanning the flame.

Market Moves & Shaky Grounds

Bitcoin’s been dancing close to its high of $124,500 after a neat 13% bounce this past week. It seems folks are dumping their gold for digital coins. Gold’s seen about a 48% rise this year, but keep an eye as its rally slows and the Bitcoin buzz grows.

The forecast’s sunny for the fourth quarter of 2025, with ETFs expected to keep pouring in. However, the crystal ball’s a bit foggy. Different banks, different tales, and plenty hanging on the macroeconomic winds, not to mention those Bitcoin-loving investors.

That’s New York’s take on the Bitcoin boom—wallets ready?

For more insights, dive into Investopedia and see where your chips fall.

The post JPMorgan and Citi Predict Bitcoin Surge from ETF Inflows This Quarter appeared first on Kingston Global Tokyo Japan.

As a quintessential New Yorker might say, there’s a storm brewing in the financial district. The big shots are lining up to file crypto ETFs, just as Gary Gensler, the head honcho at the SEC, is packing his bags. Financial titans like Tidal Financial Group, ProShares, CoinShares and VanEck are jumping in, sensing the winds are about to change.

It’s like a New York deli rush hour in the crypto ETF ecosystem. James Seyffart, a senior ETF analyst over at Bloomberg, mentioned a swarm of filings on social media platform X that caught everyone’s eye. The buzz is real, folks.

Now, let’s break it down. Tidal’s cooking up something called the Oasis Capital Digital Asset Debt Strategy ETF (DADS). They’re planning to pour investments into debt from crypto ecosystems. If you’re looking for grit, Tidal’s right in the mix.

Meanwhile, ProShares has its sights set on Solana (SOL) Futures ETFs along with ETFs linked to XRP. It’s about as cutting-edge as you can get on Wall Street. CoinShares isn’t sitting on its laurels either. They’re scheming to launch the CoinShares Digital Assets ETF, leveraging their CoinShares-Compass Crypto Market Index. All this activity is like the buzz of the A-Train at rush hour.

VanEck, on the other hand, has an interesting angle with its “Onchain Economy ETF.” Rather than direct digital assets, they’re targeting digital asset tools. Think futures contracts and digital transformation companies, the unsung heroes behind the screens.

Let’s face it, Gensler wasn’t everyone’s favorite guy on the block. Under his regime, the SEC was smacking down lawsuits against crypto moguls like Coinbase, Kraken, and Ripple Labs. Bitcoin (BTC)-linked ETFs? Only got greenlit thanks to a court nudge.

But wait, there’s a twist. Gensler’s bowing out right before they say President-elect Donald Trump is supposed to wave his second-term flag. January 20th’s the set date, marking the end of a vigorous SEC era.

For those keeping tabs, you don’t want to miss a beat. Get on board for email alerts, and don’t forget following us on X, Facebook, and Telegram for the full scoop. A little piece of advice—keep checking the Price Action and ride the Daily Hodl wave.

Keeping it Real

Now, if you’re diving into crypto investments, remember—it’s your turf and your call. The opinions floating around The Daily Hodl aren’t your ticket to investment riches. Do your homework before diving into high-risk endeavors with Bitcoin, cryptocurrencies, or digital assets. Remember, trades and transfers are on you, pal. Losses? Well, that one’s on you too. The Daily Hodl isn’t playing investment advisor here, just laying down the facts.

Generated Image: Midjourney

The post Crypto ETF Filings Increase as Companies Predict SEC Chair Gensler’s Exit: Report appeared first on Kingston Global Tokyo Japan.

Therapeutic mainstays like oncology and neuroscience have hogged the spotlight lately. With flashy billion-dollar acquisitions and groundbreaking drugs for diseases like Alzheimer’s and various cancers, who could look away? Big players like Johnson & Johnson haven’t been shy, forking over a hefty sum of $14.6 billion for neuropsychiatric leader Intra-Cellular Therapies. But wait, 2025 might be flipping the script. Enter obesity treatment and immunology – two rising stars ready to steal the show.

Immunology and inflammation hold a promising future, if you believe Andrew Pannu of Sleuth, who sees biopharma’s radar honing in on this lucrative niche. The global immunology market could balloon over $257 billion by 2032. Source, with last year’s high-stake deals setting the stage for more to come. Gilead Sciences just bet $1.7 billion on LEO Pharma’s promising molecular STAT6 program aimed at inflammatory diseases, perfectly setting the dominoes.

Amid this realm comes a fascinating twist: cell therapy. With approvals for Iovance’s Amtagvi and Adaptimmune’s Tecelra, 2024 marked a standout year. Now, cell therapy targets autoimmune diseases. The groundbreaking work of Georg Schett of the German Center for Immunotherapy showcased eight lupus patients miraculously reaching remission. The excitement is palpable, and big players are rearranging their decks.

A Time for T Cell Engagers

Let’s talk T cell engagers, the talk of the town. Andrew Pannu sees TCEs gaining traction, especially with M&A heating up. Just a few months back, GSK inked a $300 million deal for a dual CD19 and CD20-targeted TCE from Chimagen Biosciences, and they didn’t stop there. This January, Ouro Medicines kicked off with $115 million to dive into TCEs targeting immune-mediated diseases. And don’t sleep on Candid Therapeutics, aiming high with a $925 million deal with WuXi Biologics for a preclinical trispecific TCE targeting autoimmune maladies.

In oncology, TCEs are stirring excitement, especially in tackling solid tumors. Chris Bardon weighs in. Early challenges aside, the industry’s cracking the code on dosing and patient management.

Obesity’s Next Play

Obesity, the 2024 headliner, isn’t fading away. Verdiva Bio is shaking the industry with a $411 million series A. They’re going toe-to-toe with giants like Novo Nordisk and Eli Lilly, innovating oral, injectable obesity treatments. GLP-1 drugs are hot, with non-GLP-1 candidates making waves too.

GLP-1s are in their prime, says Bardon, mixing with GIP analogs for potency. Behind this promise lies potential vast revenue – possibly upwards of $50 billion. The ambition is massive.

• Verdiva Bio: $411 million raised
• Metsera: $290 million in early 2024, poised for an IPO

Neuromuscular, Kidney, and Cardiovascular Disease

In neuromuscular spaces, strides in Duchenne muscular dystrophy light the way. The landmark approval of Sarepta’s Elevidys represents a beacon of change. Stay tuned as Regenxbio and Dyne Therapeutics deliver next-gen solutions. Kidney and cardiovascular diseasessSS are similarly springing back into the spotlight, with Maze Therapeutics and Kardigan making early plays.

Macro Trends: China and Duopolies

Bigger picture? Remain aware of the growing Chinese influence on big Pharma. Global players now source many of their molecules from China. Old skepticism? Fading. Expect U.S.-China partnerships to dominate.

And those duopolies? They’re dominating spaces like obesity, Alzheimer’s, and depression. Big names like Novo Nordisk, Eli Lilly, Gilead, and Intra-Cellular continue their strangleweight on markets. But does it make sense to join the obesity bandwagon as player number nine? Perhaps, if you’re eyeing potential partnerships or combinations.

Navigating 2025, keep an eye on the shifting currents in these dynamic therapeutic areas. Whether it’s obesity, immunology, or cell therapy, the Broadway of biopharma awaits its next star players. And, as always, watch where the money goes because it rarely lies.

The post Experts Predict 2025 Investments to Focus on I&I and Obesity appeared first on Kingston Global Tokyo Japan.